Loading...

Brilliant Violet 785™ anti-mouse/human CD44 Antibody

Pricing & Availability
Clone
IM7 (See other available formats)
Regulatory Status
RUO
Other Names
Hermes, Pgp-1, H-CAM, HUTCH-1, ECMR III, gp85, Ly-24
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
IM7_BV785_061812
C57BL/6 mouse splenocytes were stained with CD44 (clone IM7) Brilliant Violet 785™.
  • IM7_BV785_061812
    C57BL/6 mouse splenocytes were stained with CD44 (clone IM7) Brilliant Violet 785™.
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
103041 125 µL 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103059 50 µg 219€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD44 is a 80-95 kD glycoprotein also known as Hermes, Pgp1, H-CAM, or HUTCH. It is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells. As B and T cells become activated or progress to the memory stage, CD44 expression increases from low or mid levels to high levels. Thus, CD44 has been reported to be a valuable marker for memory cell subsets. High CD44 expression on Treg cells has been associated with potent suppressive function via high production of IL-10. CD44 is an adhesion molecule involved in leukocyte attachment to and rolling on endothelial cells, homing to peripheral lymphoid organs and to the sites of inflammation, and leukocyte aggregation.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse,Human
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Dexamethasone-induced myeloid leukemia M1 cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the test size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.4 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone IM7 has been reported to recognize an epitope common to alloantigens and all isoforms of CD4417,18 that is located between amino acids 145 and 18620. This clone has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections6,7, complement-mediated cytotoxicity1, immunoprecipitation1,3, in vivo inhibition of DTH4,5, and spatial biology (IBEX)23,24. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103046, 103065 - 103069).

Cross-reactivity to ferret has been reported by a collaborator, but not verified in house.

Application References
  1. Trowbridge IS, et al. 1982. Immunogenetics 15:299. (ICFC, IP, CMCD)
  2. Katoh S, et al. 1994. J. Immunol. 153:3440. (ELISA)
  3. Budd RC, et al. 1987. J. Immunol. 138:3120. (IP)
  4. Camp RL, et al. 1993. J. Exp. Med. 178:497. (Block)
  5. Weiss JM, et al. 1997. J. Cell Biol. 137:1137. (Block)
  6. Frank NY, et al. 2005. Cancer Res. 65:4320. (IHC) PubMed
  7. Cuff CA, et al. 2001. J. Clin. Invest. 108:1031. (IHC)
  8. Lee JW, et al. 2006. Nature Immunol. 8:181.
  9. Zhang N, et al. 2005. J. Immunol. 174:6967. PubMed
  10. Huabiao C, et al. 2005. J. Immunol. 175:591. PubMed
  11. Gui J, et al. 2007. Int. Immunol. 19:1201. PubMed
  12. Wang XY, et al. 2008. Blood 111:2436. PubMed
  13. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  14. Yamazaki J, et al. 2009. Blood PubMed
  15. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  16. Chen YW, et al. 2010. Mol. Cancer Ther. 9:2879. PubMed
  17. Zheng Z, et al. 1995. J. Cell. Biol. 130:485.
  18. Wiranowska M, et al. 2010. Int. J. Cancer 127:532.
  19. Hirokawa Y, et al. 2014. Am J Physiol Gastrointerest Liver Physiol. 306:547. PubMed
  20. Sandmaier BM, et al. 1998. Blood 91:3494.
  21. Yang Y, et al. 2015. Hypertension. 65:1047. PubMed
  22. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  23. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  24. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Beura LK, et al. 2018. Immunity. 48:327. PubMed
  2. Abbott RK, et al. 2018. Immunity. 48:133. PubMed
  3. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  4. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
  5. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  6. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  7. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  8. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  9. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  10. Wu B, et al. 2020. Int J Biol Sci. 16:1526. PubMed
  11. Pustlauk W, et al. 2020. Sci Rep. 10:5951. PubMed
  12. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  13. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  14. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  15. Opata M, et al. 2015. J Immunol. 194:5346. PubMed
  16. Kaveh D, et al. 2016. Vaccine. 34:4003-4011. PubMed
  17. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  18. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  19. Gurusamy D, et al. 2020. Cancer Cell. 37(6):818-833.e9. PubMed
  20. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  21. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  22. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  23. Sun X, et al. 2021. Nature. 599:673. PubMed
  24. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  25. Matas-Rico E, et al. 2021. Cell Rep. 37:110013. PubMed
  26. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  27. Woodring T, et al. 2022. iScience. 25:104934. PubMed
  28. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  29. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
  30. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  31. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  32. Pierson M, et al. 2021. Curr Protoc. 1:e53. PubMed
  33. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  34. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  35. Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed
  36. Wu B, et al. 2023. J Immunother Cancer. 11: . PubMed
  37. Guo A, et al. 2022. Nature. 607:135. PubMed
  38. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  39. Ludwig J, et al. 2023. NPJ Vaccines. 8:52. PubMed
RRID
AB_11218802 (BioLegend Cat. No. 103041)
AB_2571953 (BioLegend Cat. No. 103059)

Antigen Details

Structure
Variable splicing of CD44 gene generates many CD44 isoforms, 80-95 kD
Distribution

All leukocytes, epithelial cells, endothelial cells, hepatocytes, mesenchymal cells

Function
Leukocyte attachment and rolling on endothelial cells, stromal cells and ECM
Ligand/Receptor
Hyaluronan, MIP-1β, fibronectin, collagen
Cell Type
B cells, Endothelial cells, Epithelial cells, Leukocytes, Mesenchymal cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Immunology, Stem Cells
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Haynes BF, et al. 1991. Cancer Cells 3:347.
3. Goldstein LA, et al. 1989. Cell 56:1063.
4. Mikecz K, et al. 1995. Nat. Med. 1:558.
5. Hegde V, et al. 2008. J. Leukocyte Biol. 84:134.
6. Liu T, et al. 2009. Biol. Direct 4:40.

Gene ID
12505 View all products for this Gene ID 960 View all products for this Gene ID
UniProt
View information about CD44 on UniProt.org
Go To Top Version: 3    Revision Date: 03-17-2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account